摘要
[目的 ] 观察拉米呋定治疗B、C基因型慢性乙型肝炎病人的临床疗效。 [方法 ] 3 5例B型慢性乙型肝炎病人及 18例C型慢性乙型肝炎病人同时给予拉米呋定 10 0mg ,每天 1次 ,疗程 1年 ,观察血清病毒学指标、肝功能变化及药物不良反应。 [结果 ] B型慢性乙型肝炎病人治疗后HBV -DNA阴转率、ALT复常率均显著高于C型慢性乙型肝炎病人 ,差异均有显著性 (P <0 .0 5 )。 [结论 ] 拉米呋定对B基因型的慢性乙型肝炎病人的临床疗效高于C基因型慢性乙型肝炎病人。
Objective] To observe the clinical effect of lamivudine to type B and type C of chronic HBV patients. [Methods] Lamivudine 100mg per day for one year were given to 35 cases type B HBV patients and 18 cases type C HBV patients. The virus index in serum, the change of the function of liver and the adverse effects of the drug were observed. [Results] After treatment, the rate of detection of HBV turned from positive to negative and rate of ALT turned normal between the two groups obviously differed(P<0.05). [Conclusion] The clinical effect of lamivudine in genotype B of the chronic HBV patients is higher than that of the genotype C ones. Using lamivudine to treat chronic HBV patients with copy of virus is effective.
出处
《上海预防医学》
CAS
2004年第2期67-68,共2页
Shanghai Journal of Preventive Medicine
